RJ Hamster
Med-X is gearing up for a possible NASDAQ listing…
| Med-X is gearing up for a possible NASDAQ listing (ticker: MXRX). But the real opportunity is now – before public health adoption accelerates.In certain use cases, Med-X’s all-natural pesticides have outperformed chemical brands in independent lab tests, delivering safer solutions without sacrificing results.Now, Med-X is approaching a major real-world validation catalyst: Florida Mosquito Control Districts are independently testing Nature-Cide as an adulticide, larvicide, and barrier treatment – with the goal of adding it to their official rotation.Florida has the most well-funded mosquito control districts in the United States and carries the highest responsibility for controlling mosquito-borne threats. These districts are known as leaders and innovators in Integrated Mosquito Management – meaning that when Florida adopts a solution, other regions often follow.And right now, these districts need better options.Public scrutiny over the chemical pesticides traditionally used in mosquito control is rising fast – especially around communities, schools, and waterways. Nature-Cide’s plant-based approach offers a potential alternative that aligns with performance demands while reducing toxicity concerns.NASDAQ Ticker: MXRX Reserved! The Real Opportunity to Become a Shareholder Is Now!Med-X has earned national and international recognition for providing effective alternatives to conventional pesticides across residential, commercial, and agricultural sectors. Proudly produced in the USA under strict quality standards, Nature-Cide reflects their commitment to sustainable pest management innovation.With $6.4M in sales in just four years, expanding into 41 international markets, Med-X is getting ready for the next step…Simpler. Safer. More Effective Pesticides.Become a Med-X shareholder at $4 per share before their NASDAQ plans unfold.DisclosuresThis is a paid advertisement for Med-X’s Regulation A+ Offering. Please read the offering circular at invest.medx-rx.com |
Thank you for subscribing to DividendStocks.com‘s daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.
This email message is a sponsored email from Med-X, a third-party advertiser of DividendStocks.com and MarketBeat.
If you need help with your account, please feel free to email MarketBeat’s U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl., Suite 620, Sioux Falls, S.D. 57103-7078. United States..
